暂无摘要。

At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive, HER2-negative disease. The pan-PI3K inhibitor buparlisib showed some activity in combination with fulvestrant after failure of everolimus in the BELLE-3 trial. PIK3CA mutation detected in circulating tumor DNA (ctDNA) was predictive for a buparlisib efficacy. Unfortunately, the unfavorable toxicity profile precludes further development of this drug. Nonetheless, PI3K seems to be a valid target in tumors resistant to mTOR inhibition. The BROCADE phase II trial failed to show a statistically significant benefit by the addition of the PARP inhibitor veliparib to carboplatin and paclitaxel in patients with BRCA1/2 germline mutation. The overall response rate, however, was statistically significant higher in the veliparib arm compared to the placebo arm. Data from the phase III trial BROCADE-3 are awaited. Finally, the TNT trial did not identify further biomarkers, in addition to BRCA1/2 germline mutation, for carboplatin benefit in patients with metastatic triple-negative breast cancer.

Bobby Reddy speaks to Gemma Westcott, Commissioning Editor: Dr Reddy graduated from the UCLA School of Medicine in 1996. Shortly after, he obtained an internship and did his residency in Internal Medicine at Harbor UCLA Medical Center. He then went on to do his fellowship in Hematology and Oncology at City of Hope. Since then, he has been working in private practice (full and part time) for the past 11 years and has had an academic appointment as teaching faculty at Harbor UCLA. Prior to his current role, Dr Reddy worked as a senior medical director as Caris Life Sciences.